Healthcare

Julie Grant

General Partner / West Coast

Since 2013

Julie is motivated by products that tangibly improve patients’ lives. She invests in early stage biopharma and digital health ventures, and leads new company formation efforts as an executive. Julie previously worked at Genentech across development and commercial divisions and also served on the board of the Biden Cancer Initiative and co-chaired Planned Parenthood NorCal’s IT Advisory Board. She holds an M.B.A. from Stanford, an MPhil. in BioScience Enterprise from Cambridge and a B.S. in Molecular Biophysics and Biochemistry from Yale.

Julie in 5

Origins: Grew up next to The Second City in Chicago

Interests: Maintaining a strict diet of daily dark chocolate consumption

Travel: Weekend skiing & hiking retreats in the Western mountain ranges

Accomplishments: College sailing national champion

Bucket List: Skiing in Japan

Investments

Current

Previous

Latest

MedCityNews: Julie Grant on how the pandemic has changed investing

FierceBiotech: COVID-19 close-up: Nocion CEO Batycky on controlling cough to control spread

WSJ Pro VC: Cancer drugmaker Day One Biopharmaceuticals launches with $60 million

STAT News: Startup Spotlight - Aiming to speed precision cancer therapies to children

Julie Grant: Cancer drug development comes of age - The inspiration behind Day One Biopharmaceuticals

FierceBiotech: Day One debuts with $60M to change cancer care—starting with children

MedCity News: How are healthcare VCs in every sector handling Covid-19?

BioCentury: We’ve moved on from nude women parties. That’s only a small part of the progress.

Annual Women Who Venture Gathering 2020

FierceBiotech: Canaan Partners promotes Julie Grant to general partner

Growth from within: Brendan Dickinson and Julie Grant promoted to General Partners

FierceBiotech: Nocion Therapeutics named to Fierce 15

FierceBiotech: Nocion launches with $27M and 'charged drugs' to selectively target pain

Business Insider: Nocion raises $27M to make a new kind of painkiller as the race to replace opioids heats up

STAT News: How one company, Nocion, thinks unraveling cough can provide a new way to treat pain

Julie Grant: Announcing Nocion Therapeutics, a novel approach to neurogenic inflammation

Business Insider: Julie Grant named 40-and-under Silicon Valley biotech investing star

Nina Kjellson: In case of emergency -- expert tips for weathering a crisis

Endpoints Under 40 Feature: Julie Grant’s views on the future of biopharma

Spotlight on Wende Hutton’s 25 years in venture capital

STAT News: Julie Grant on how biotech’s latest bubble might go pop

CNBC: After a miserable 2017, VCs offer predictions on digital health IPOs for 2018

CNBC: 11 women who prove that health tech investing isn’t a boys’ club

Fierce Biotech: Canaan unveils $800 million fund for fresh wave of biotech bets

BioTech Nation Podcast: Women in biotech venture capital

SF Business Times: Life sciences veterans reflect on the past, present and future of Bay Area biotech

Silicon Valley Business Journal: Women of Influence 2017

Protagonist Therapeutics

Julie in 5

Origins: Grew up next to The Second City in Chicago

Interests: Maintaining a strict diet of daily dark chocolate consumption

Travel: Weekend skiing & hiking retreats in the Western mountain ranges

Accomplishments: College sailing national champion

Bucket List: Skiing in Japan